poisar

Stocks · News reference

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

BenzingaAvi Kapoor

Wall Street analysts change outlook on top names. See all rating changes, upgrades, downgrades and initiations at Benzinga's analyst ratings page.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaAvi Kapoor

    Jim Cramer Says Buy Carpenter Technology, Calls This IT Services Stock a 'Value Trap'

    Cramer recommends buying Carpenter Technology (NYSE: CRS) and calls DXC Technology (NYSE: DXC) a value trap. Senseonics Holdings (NASDAQ: SENS) posts upbeat sales and Ubiquiti (NYSE: UI) reports worse-than-expected results. Hess Midstream (NYSE: HESM) is a winner while Zeta Global (NYSE: ZETA) announces a new CMO. UL Solutions (NYSE: ULS) is a potential buy and Coupang (NYSE: CPNG) is not recommended, but MercadoLibre (NASDAQ: MELI) and Amazon (NASDAQ: AMZN) are worth considering.

  2. The Motley FoolSara Appino

    Amazon.com vs. Coupang: Which Consumer Stock Is a Better Buy in 2026?

    The article compares Amazon and Coupang as e-commerce investment options for 2026. Amazon demonstrates superior financial health with a 10.8% net margin, $3.0T market cap, and diversified revenue streams including AWS and advertising. Coupang, despite 14.1% revenue growth, struggles with a 0.6% net margin, recent data breach fallout, regulatory fines, and currency headwinds. The author recommends Amazon for long-term investors due to its scale, profitability, momentum, and lower risk profile compared to Coupang's multiple near-term challenges.

  3. Globenewswire IncBcc Research

    Global Pathology Services Market to Reach $307.9 Billion by 2030, Driven by Rising Cancer Incidence and AI-Enabled Diagnostic Innovation

    The global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.

  4. Zacks Investment ResearchZacks.Com

    Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

    RSPH, an equal-weight healthcare ETF launched in 2006, has gained 17.92% year-to-date and 29.15% over the past year as of August 31, 2026. With $826.52 million in assets and a 0.40% expense ratio, it offers diversified exposure to 63 healthcare holdings. However, cheaper alternatives like VHT (0.09% expense ratio) and XLV (0.08% expense ratio) may be more suitable for cost-conscious investors seeking lower-risk options.